Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences (Nasdaq: CSTL) announced a groundbreaking ceremony for its new corporate headquarters in Friendswood, Texas. The event, scheduled for Oct. 22, 2024, marks the start of construction on a four-story, 80,000 square foot Class A office building. The 23-acre campus will feature amenities like a covered rooftop deck, corporate fitness center, walking trails, and covered pavilions.
Derek Maetzold, CEO of Castle Biosciences, emphasized the company's commitment to its employees and the community. The new facility is designed to foster collaboration and support future growth. Jason Tramonte Jr., the project's architect, highlighted the employee-centric focus in the design. Castle Biosciences, founded in 2008, also operates clinical laboratories in Phoenix and Pittsburgh.
Castle Biosciences (Nasdaq: CSTL) ha annunciato una cerimonia di apertura per il suo nuovo quartier generale a Friendswood, Texas. L'evento, previsto per 22 ottobre 2024, segna l'inizio della costruzione di un edificio per uffici di Classe A di 80.000 piedi quadrati su quattro piani. Il campus di 23 acri offrirà servizi come una terrazza coperta, un centro fitness aziendale, sentieri pedonali e padiglioni coperti.
Derek Maetzold, CEO di Castle Biosciences, ha sottolineato l'impegno dell'azienda verso i propri dipendenti e la comunità. La nuova struttura è progettata per favorire la collaborazione e supportare la crescita futura. Jason Tramonte Jr., l'architetto del progetto, ha evidenziato l'attenzione rivolta ai dipendenti nel design. Castle Biosciences, fondata nel 2008, gestisce anche laboratori clinici a Phoenix e Pittsburgh.
Castle Biosciences (Nasdaq: CSTL) anunció una ceremonia de inauguración para su nueva sede corporativa en Friendswood, Texas. El evento, programado para el 22 de octubre de 2024, marca el inicio de la construcción de un edificio de oficinas de Clase A de 80,000 pies cuadrados de cuatro pisos. El campus de 23 acres contará con comodidades como una terraza cubierta, un centro de fitness corporativo, senderos para caminar y pabellones cubiertos.
Derek Maetzold, CEO de Castle Biosciences, enfatizó el compromiso de la empresa con sus empleados y la comunidad. La nueva instalación está diseñada para fomentar la colaboración y apoyar el crecimiento futuro. Jason Tramonte Jr., el arquitecto del proyecto, destacó el enfoque centrado en el empleado en el diseño. Castle Biosciences, fundada en 2008, también opera laboratorios clínicos en Phoenix y Pittsburgh.
캐슬 바이오사이언스(Castle Biosciences, Nasdaq: CSTL)는 텍사스 주 프렌즈우드에 새 본사를 위한 기념식을 발표했습니다. 2024년 10월 22일로 예정된 이 행사는 80,000 평방피트 규모의 4층짜리 A급 오피스 건물의 건설 시작을 알립니다. 23에이커 규모의 캠퍼스에는 옥상 데크, 기업 피트니스 센터, 산책로 및 차양이 있는 파빌리온과 같은 편의시설이 갖춰질 예정입니다.
캐슬 바이오사이언스의 CEO인 데레크 메이츠골드(Derek Maetzold)는 직원과 지역사회에 대한 회사의 헌신을 강조했습니다. 새로운 시설은 협업을 촉진하고 미래 성장을 지원하도록 설계되었습니다. 프로젝트의 설계자 제이슨 트라마onte 주니어(Jason Tramonte Jr.)는 디자인에 있어 직원 중심의 접근을 강조했습니다. 2008년에 설립된 캐슬 바이오사이언스는 피닉스와 피츠버그에도 임상 실험실을 운영하고 있습니다.
Castle Biosciences (Nasdaq: CSTL) a annoncé une cérémonie de pose de la première pierre pour son nouveau siège social à Friendswood, Texas. L'événement, prévu pour le 22 octobre 2024, marque le début de la construction d'un bâtiment de bureaux de Classe A de 80 000 pieds carrés sur quatre étages. Le campus de 23 acres disposera d'équipements tels qu'une terrasse sur le toit, un centre de fitness d'entreprise, des sentiers piétonniers et des pavillons couverts.
Derek Maetzold, PDG de Castle Biosciences, a souligné l'engagement de l'entreprise envers ses employés et la communauté. La nouvelle installation est conçue pour favoriser la collaboration et soutenir la croissance future. Jason Tramonte Jr., l'architecte du projet, a mis en avant l'orientation centrée sur l'employé dans le design. Castle Biosciences, fondée en 2008, exploite également des laboratoires cliniques à Phoenix et Pittsburgh.
Castle Biosciences (Nasdaq: CSTL) hat eine Grundsteinlegung für seinen neuen Unternehmenssitz in Friendswood, Texas, angekündigt. Die Veranstaltung, die für 22. Oktober 2024 geplant ist, markiert den Baubeginn eines vierstöckigen, 80.000 Quadratfuß großen Bürogebäudes der Klasse A. Der 23 Acres große Campus wird Annehmlichkeiten wie eine überdachte Dachterrasse, ein Unternehmensfitnesscenter, Wanderwege und überdachte Pavillons bieten.
Derek Maetzold, CEO von Castle Biosciences, betonte das Engagement des Unternehmens für seine Mitarbeiter und die Gemeinschaft. Die neue Einrichtung soll die Zusammenarbeit fördern und zukünftiges Wachstum unterstützen. Jason Tramonte Jr., der Architekt des Projekts, hob die mitarbeiterzentrierte Ausrichtung im Design hervor. Castle Biosciences, 2008 gegründet, betreibt auch klinische Labore in Phoenix und Pittsburgh.
- Construction of a new, larger corporate headquarters indicates potential for company growth and expansion
- Employee-focused design may improve workplace satisfaction and productivity
- None.
Castle Biosciences' New Corporate Headquarters in
“We are thrilled to have broken ground on our new corporate headquarters in
The Company’s four-story headquarters building will encompass approximately 80,000 square feet of Class A office space. Unique amenities include a covered rooftop deck providing outdoor collaborative space and a corporate fitness center planned for the ground level. The 23-acre wooded campus has been thoughtfully designed with walking trails and covered pavilions to allow nature respites throughout the workday.
“It was always important to Castle that we design the new headquarters with an employee-centric focus,” said Jason Tramonte, Jr., AIA, IIDA, architect and owner of Tramonte Design Studio, the architecture and interior design firm on the project. “Each detail — from the big-picture campus plan down to the individual office spaces — was carefully planned to foster an environment conducive to a myriad of work styles, whether collaborative or private, indoor or outdoor, or any combination thereof.”
In addition to their
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241002781365/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When is Castle Biosciences (CSTL) holding the groundbreaking ceremony for its new headquarters?
Where will Castle Biosciences' (CSTL) new corporate headquarters be located?
How large will Castle Biosciences' (CSTL) new headquarters building be?
What amenities will Castle Biosciences' (CSTL) new headquarters feature?
